Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Pethidine Injection BP 50mg/ml

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Pethidine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Pethidine hydrochloride
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Pethidine Injection is a type of medicine called an opioid analgesic. It contains pethidine which belongs to a class of medicines called opioids, which are 'pain relievers. An analgesic is a medicine that can be used to relieve pain. This medicine has been prescribed for you for relief of moderate to severe pain. Including pain associated with childbirth, or during an anaesthetic or following an operation. As well as relieving pain, pethidine has other effects including a sedative (calming) effect. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

What you need to know before you take it

Pethidine Injection You should not be given Pethidine Injection

  • if you are allergic to Pethidine Hydrochloride or any of the other ingredients of this medicine (listed in section 6), or to other strong pain relievers, such as morphine
  • if you have any problems that affect your breathing including chronic bronchitis or asthma, shallow breathing or other breathing difficulties
  • if you are taking monoamine oxidase inhibitors (MAOIs) or have been taking them within the last two weeks. MAOIs (eg. moclobemide, phenelzine or isocarboxazid, selegiline and rasagiline) are medicines used to treat depression. (see 'Other medicines and Pethidine Injection')
  • if you are taking ritonavir used for treatment of HIV infection and isoniazid for tuberculosis
  • if you are suffering from severe headaches or you have recently suffered a head injury,
  • if you have any conditions associated with raised pressure in the brain or a tumour of the adrenal gland (pheochromocytoma).
  • if you have any liver or kidney problems
  • if you suffer from alcoholism
  • if you suffer from a convulsive disorder (fits) such as epilepsy
  • if you are suffering from a condition known as delirium tremens, caused by withdrawal from alcohol
  • if your heartbeat is faster than usual
  • if you suffer from diabetes. Patients in a coma should not be given this medicine. Speak to your doctor if one of these applies to you before you are given this medicine. Warnings and precautions Talk to your doctor or pharmacist before being given Pethidine Injection
  • if you are in shock, the symptoms of which include sweating, a fast pulse and cold, clammy skin
  • if you have an underactive thyroid gland (which may cause tiredness, intolerance to cold, constipation, and puffiness of the face)
  • if you have underactive adrenal glands (Addison's disease) or suffer from problems related to your adrenal gland (the organ responsible for stress levels), including adrenocortical insufficiency (a lack of the hormones produced by the adrenal gland)
  • if you have a condition that makes you have fits, eg. epilepsy
  • if you have problems with your heart causing an increased heart rate
  • if you have a problem with your bowel, liver, kidneys or gall bladder
  • if you are in a collapsed state from loss of blood or fluid
  • if you are feeling weak and run-down
  • if you are complaining of headache and vomiting
  • if you suffer from sickle cell anaemia
  • if you are elderly and in a poor state of health
  • if you have an enlarged prostate gland causing difficulty passing water (men only)
  • if you have low blood pressure
  • if you have weak muscular movement
  • if you have diseases of the stomach or intestine
  • if you have lung problems
  • if you have been drinking alcohol within the previous 24 hours.
  • if you are taking any medicine from the group of medicines known as benzodiazepines. Taking these medicines with Pethidine may result in sedation, difficulties in breathing (respiratory

depression), coma and may be fatal. Even if benzodiazepines are prescribed, your doctor may need to change the dose, the duration of treatment or monitor you regularly. Talk to your prescriber before taking this medicine if you:   

are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs. have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating when you have stopped taking alcohol or drugs feel you need to take more of Pethidine Injection to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever.

Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. If you are elderly or ill, or your baby or child is being given Pethidine Injection, special care will be taken. This medicine may cause difficulty in breathing (respiratory depression) in neonates and young infants. If any of the above apply to you or your child, please tell your doctor before being given Pethidine Injection. Other medicines and Pethidine Injection Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pethidine Injection must not be used with drugs used to treat severe depression, such as rasagiline or moclobemide, or if you are within 2 weeks of discontinuing them.

A large number of drugs can interact with Pethidine Injection which can significantly alter their effects. These drugs include:

  • medicines for depression (eg. tricyclic antidepressants such as amitriptyline) and medicines for anxiety (anxiolytics) (eg. benzodiazepines such as diazepam)
  • medicines used to help you to sleep (hypnotics)
  • medicines for schizophrenia or other serious mental illness, such as phenothiazines (which may be present in various medicines including some for treating allergic disorders, nausea (feeling sick) and vomiting (being sick)
  • CNS depressants (drugs that act on the brain and make you feel drowsy or faint). These include sleeping pills, antihistamines (medicines used to treat allergies) that make you drowsy, medicines used to treat certain mental disorders.
  • sedatives, sleeping tablets or barbiturates (eg. phenobarbitone for epilepsy)
  • cimetidine (for heart burn or stomach ulcers)
  • duloxetin (used to treat depression)
  • domperidone and metoclopramide (used for disorders of the gastrointestinal tract)
  • monoamine oxidase inhibitor A and B (used to treat depression)
  • ritanovir (antiviral), a medicine used to treat HIV
  • pain relievers and other opioid medicines
  • anticholinergic drugs (eg. for a tummy or intestine problem, or for a "weak" bladder or as an inhaler for a breathing problem)
  • selegiline, a medicine used to treat Parkinson's disease
  • phenytoin, a medicine used to treat fits (antiepileptic medicine)
  • isoniazid (used to treat tuberculosis)
  • ciprofloxacin, an antibiotic used to treat a number of bacterial infections
  • mexiletine, a medicine used to treat seriously irregular heartbeats
  • concomitant use of Pethidine and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe Pethidine together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. If you are already taking one of these medicines, speak to your doctor before you receive Pethidine Injection. Pethidine Injection with food, drink and alcohol You must avoid drinking alcohol whilst being given Pethidine Injection as it may increase the risk of developing breathing problems and low blood pressure. Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Pregnancy Do not take Pethidine Injection if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Pethidine Injection during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Pethidine Injection may cause breathing problems in newborns. Breast-feeding Do not take Pethidine Injection while you are breastfeeding as pethidine passes into breast milk and will affect your baby. Driving and using machines Pethidine Injection can cause drowsiness and clouding of consciousness which could interfere with your ability to use machines. Do not operate machinery whilst you are taking this medicine. When your Pethidine Injection treatment has stopped, ask your doctor when it will be safe for you to use machines. The medicine can affect your ability to drive as it may make you sleepy or dizzy.

  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive if this medicine affects your ability to drive.
  • However, you would not be committing an offence if: o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and o It was not affecting your ability to drive safely. Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Tolerance and dependence: Pethidine Injection can become less effective with repeated use. This is called tolerance and it means that the dose may have to be increased for Pethidine Injection to remain effective. If Pethidine Injection is used repeatedly, it becomes habit-forming. This is called dependence and if Pethidine Injection treatment is suddenly stopped, unpleasant withdrawal symptoms may occur. Information on Sodium content This medicine contains less than 1mmol sodium (23mg) per dose, that is to say essentially 'sodium-free'.

How to take it

to you

Pethidine Injection may be administered by injection into a muscle (intramuscular), or into the tissue just below the skin (subcutaneous) or by slow injection into the vein (intravenous). Your prescriber should have discussed with you, how long the course of injection will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults: A single dose of between 25 – 100mg may be injected into a muscle or into the tissue just beneath the skin. For injection into a vein, a single dose of between 25 – 50mg may be given slowly. These single doses should not usually be repeated more frequently than every 4 hours if required. Elderly Patients or for Patients in a Weakened Condition: The initial dose should not exceed 25mg, because elderly patients or those in a weakened condition are more sensitive to the unwanted effects of pethidine. Use in children The usual single dose is 0.5 to 2.0mg per kilogram of body weight by injection into a muscle. If necessary, this dose may be repeated, allowing at least 4 hours between doses. To ensure that the correct dose is given, use of a special syringe with fine markings is recommended for administration in children. Alternatively, the solution may be diluted in Water for Injections to make it easier to measure the dose accurately. If you have any further questions on the use of this product, ask your doctor or pharmacist. If you think you have been given more Pethidine Injection than you should The symptoms and signs of taking too much of this medicine include shallow breathing, drowsiness, incoordination, coma, seizures, blue skin and lips, eye closure (miosis), shaking, cold, clammy skin, drop in body temperature, slow heartbeat and low blood pressure. This medicine will be given to you in hospital so it is unlikely you will receive too much. Your doctor has information on how to recognise and treat an overdose. If you feel unwell after being given this medicine, or are at all concerned you have been given too much, tell your doctor or nurse immediately. If you think you have missed a dose of Pethidine Injection Tell your doctor, nurse immediately. If you have any further questions on the use of this medicine, ask your doctor or nurse. If you stop taking Pethidine Injection Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them. Repeated use of pethidine can result in tolerance and addiction These are more common when Pethidine is given into a vein. All medicines can cause allergic reactions although serious allergic reactions are rare. Any sudden wheeziness and tightness of the chest, difficulty in breathing, swelling of the eyelids, face or lips, skin lumps or hives, skin rash (red spots) or itching (especially affecting your whole body), fever and collapse should be reported to a doctor immediately. The most serious side effects are difficulty breathing and low blood pressure. Other side effects that may occur include: Uncommon: may affect up to 1 in 100 people:

  • Drug Withdrawal: When you stop taking Pethidine injection, you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. Not known: frequency cannot be estimated from the available data:
  • disturbances in eyesight
  • pin-point pupils
  • dry eye
  • delay in blinking reflex when things are close to your eye
  • feeling sleepy
  • weakness, headache,
  • fits
  • CNS excitation
  • a feeling of dizziness or spinning
  • fainting
  • hallucinations (seeing or hearing things that are not there)
  • dependence and addiction (see section "How do I know if I am addicted?")
  • confusion
  • mood changes (symptoms include feeling tense and restless)
  • flushing of the face
  • itch, rash, wheals (raised, itchy area of skin),
  • pain, and redness or itching over site of injection
  • difficulty in passing urine and swelling over the body especially on legs
  • feeling restless or agitated
  • trembling, uncoordinated movements
  • dry mouth, constipation, abdominal pain
  • spasms in the lower abdomen
  • also in elderly patients there is an increased risk of delirium (confusion, slurred speech and hallucinations).
  • irregular heartbeats, fast or slow
  • palpitations (an irregular heart rhythm or missed beats)
  • lightheadedness
  • feeling sick (nausea), being sick (vomiting), sweating
  • rapid changes in the blood pressure
  • feeling faint on standing up from a seated
  • slowed breathing
  • low blood pressure, the symptoms of which include feeling dizzy or light-headed, feeling weak and fainting
  • high blood pressure
  • dilatation of blood vessels (vasodilatation)
  • increased or decreased body temperature
  • overactive reflexes
  • feeling overly happy (euphoria) or overly sad (dysphoria)
  • anxiety, nervousness
  • reduced sex drive
  • difficulty achieving or maintaining an erection
  • hypothermia, the symptoms of which include shivering, drowsiness and feeling weak
  • muscle twitching. How do I know if I am addicted? If you notice any of the following signs whilst taking Pethidine Injection, it could be a sign that you have become addicted.
  • You need to take the medicine for longer than advised by your prescriber
  • You feel you need to use more than the recommended dose
  • You are using the medicine for reasons other than prescribed
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again If you notice any of these signs, it is important you talk to your prescriber If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Pethidine Injection Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and ampoule label after 'Exp'. The expiry date refers to the last day of that month. Do not store above 25°C. Keep the ampoules in the outer carton in order to protect from light. The product should not be used after the expiry date printed on the ampoule or carton. If only part of the contents of an ampoule is used, the remaining solution should be discarded.

Contents of the pack and other information

What Pethidine Injection contains

  • The active substance is pethidine hydrochloride.
  • The other ingredients are sodium hydroxide or dilute hydrochloric acid in water for injections BP. What Pethidine Injection looks like and contents of pack Pethidine Injection is a clear, colourless, sterile solution. Each 1ml of solution contains 50mg of pethidine hydrochloride. The solution is presented in clear glass ampoules (bottles), containing either 1ml or 2ml. The ampoules are then packed in cardboard cartons with 10 ampoules per box. Marketing Authorisation Holder: Mercury Pharmaceuticals Limited Dashwood House, 69 Old Broad Street, London, EC2M 1QS, United Kingdom Manufacturer: B. Braun Melsungen AG, Mistelweg 2, 12357 Berlin, Germany. This leaflet was last revised in August 2023

Frequently asked questions about Pethidine Injection BP 50mg/ml

How do I take Pethidine Injection BP 50mg/ml?

Pethidine Injection BP 50mg/ml comes as injection containing 50mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Pethidine Injection BP 50mg/ml?

The active substance in Pethidine Injection BP 50mg/ml is pethidine hydrochloride.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Pethidine Injection BP 50mg/ml, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Pethidine Injection BP 50mg/ml without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Pethidine hydrochloride (3 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Pethidine hydrochloride may be used as an analgesic for the relief of moderate to severe pain including: obstetric analgesia; pre-operative medication and analgesia during anaesthesia; post-operative analgesia.

4.2. Posology and method of administration

Posology

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with pethidine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Adults

The following single doses may be used and should not usually be repeated more frequently than four hourly; Subcutaneous or intramuscular injection: 25 - 100mg. Intravenous injection: 25 - 50mg.

Elderly or debilitated patients

The initial dose should not exceed 25mg, because of the particular sensitivity among elderly or debilitated patients to the central depressant effects of pethidine.

Paediatric population

The usual single dose is 0.5 to 2mg/kg body weight by intramuscular injection. If necessary, this dose may be repeated, allowing a minimum of four hours between doses. Use of a small graduated syringe is recommended for the accurate administration of dosages in children. In the absence of graduated syringes, the solution should be diluted with Water for Injections before measuring the dose.

Method of administration

Pethidine Injection may be administered by subcutaneous, intramuscular or slow intravenous injection.

4.3. Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Use of pethidine should be avoided in patients with diabetic acidosis where there is danger of coma.

• In comatose patients

• It also contra-indicated in conditions associated with raised intracranial pressure and in head injury (opioid analgesics interfere with pupillary responses vital for neurological assessment).

• Use of pethidine in patients with Phaeochromocytoma may result in hypertensive crisis.

• Acute respiratory depression, severe obstructive airways disease or acute asthma and when there is risk of paralytic ileus or obstructive airways disease.

• Use in patients receiving monoamine oxidase inhibitors (including moclobemide, and the monoamine B inhibitors selegiline and rasagiline) or within two weeks following their withdrawal.

• It should not be administered to patients with severe renal impairment or severe hepatic impairment.

• Should be avoided in patients with acute alcoholism, delirium tremens or in those with convulsive states such as status epilepticus.

• Pethidine should not be administered to patients receiving ritonavir and isoniazid.

• Use of pethidine should be avoided in patients with supraventricular tachycardia.

4.4. Special warnings and precautions for use

Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).

If the intravenous route is being used, pethidine should be given slowly in order to reduce the risk of adverse reactions.

Extreme care is required when administering pethidine to patients with asthma, severe cor pulmonale or reduced respiratory function.

Pethidine should be used with caution or in reduced doses in patients with myasthenia gravis. Pethidine should only be used with caution and in reduced dosage in neonates and premature infants, elderly and debilitated patients and in patients with head injuries, severe hepatic or renal impairment. Renal impairment may result in accumulation of the potentially toxic metabolite norpethidine, particularly with repeat dosing. All of these patient groups may experience increased or prolonged effects of the product.

Pethidine should be used with caution in patients with hypothyroidism, adrenocortical insufficiency, shock, and supraventricular tachycardia.

Although less spasmogenic than morphine, pethidine may precipitate spasm of the ureter or Sphincter of Oddi. Subsequently it should be used with caution in patients with prostatic hypertrophy and biliary tract disorders including those with pain secondary to gallbladder pathology.

Caution is also required in patients with acute alcoholism, raised intracranial pressure, or history of convulsive disorders, existing hypotension as it may reduce the blood pressure further, myasthenia gravis.

In addition it should be avoided in patients with obstructive or inflammatory bowel disorders due to its effects on the gastrointestinal tract where it may precipitate toxic megacolon.

Drug dependence, tolerance and potential for abuse

For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).

Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.

A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.

Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.

The risks of developing tolerance should be explained to the patient.

Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.

Patients should be closely monitored for signs of misuse, abuse, or addiction.

The clinical need for analgesic treatment should be reviewed regularly.

Drug withdrawal syndrome

Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Pethidine.

Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.

The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.

Hyperalgesia

Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.

Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:

Concomitant use of Pethidine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Pethidine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Paediatric population

Pethidine has a slower elimination rate and a larger inter-subject variability in neonates and young infants compared to older children and adults, which may lead to dose related reactions such as respiratory depression. If pethidine use is contemplated in neonates or young infants (up to 12 months), any potential benefits of the drug need to be weighed against the relative risk to the patient.

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

4.5. Interaction with other medicinal products and other forms of interaction

Monoamine Oxidase Inhibitors

The concurrent use of MAOIs (including moclobemide) is contra-indicated (see section 4.3) as they may result in CNS excitation or depression.

Very severe reactions including coma, respiratory depression, cyanosis and hypotension have occurred in patients administered monoamine inhibitors (MAOIs). Pethidine should not be administered to patients taking MAOIs or to those who have taken MAOIs within 14 days (see section 4.3). The interaction of pethidine with MAOIs may result in Serotonin syndrome.

CNS depressants

The central depressant effects of pethidine may be potentiated by the concurrent use of other central nervous system depressants including anxiolytics and sedatives, hypnotics, barbiturates and tricyclic antidepressants, other analgesics, alcohol and general anaesthetics; respiratory depression, hypotension and profound sedation or coma may result.

Opioid agonists

Additive effects on CNS depression, respiratory depression and hypotension can occur with concomitant use of opioid agonist analgesics.

MAO-B inhibitors

Concomitant use of MAO-B inhibitors such as selegiline or rasagiline is contraindicated (see section 4.3) as this may lead to hyperpyrexia and CNS toxicity.

Rasagiline should not be given with pethidine as there is risk of CNS toxicity, its use should be avoided for two weeks after taking rasagiline.

Anticonvulsants

Administration of phenytoin may cause an increase in hepatic metabolism of pethidine and subsequently increased levels of norpethidine (a toxic metabolite).

Antipsychotics

Severe hypotension may occur when pethidine is administered to patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or by the administration of drugs such as phenothiazine.

Histamine H2 antagonists

Cimetidine inhibits metabolism of pethidine and therefore increases plasma concentration.

Anti-virals

Plasma concentrations of pethidine may be decreased by concomitant administration of ritonavir, however levels of norpethidine (a toxic metabolite) may rise. Concomitant administration of ritonavir, isoniazid and pethidine should be avoided (see section 4.3).

Effects of pethidine on other drugs

Pethidine antagonize effects of domperidone and metoclopramide on gastro-intestinal activity.

The plasma levels of ciprofloxacin may be reduced in the presence of opiate premedicants.

Plasma levels of mexiletine may also be reduced in the presence of opioid analgesics. Use of pethidine in prolonged increasing dosage or concomitantly with anticholinergics may result in neurotoxicity in patients with renal failure, cancer or sickle cell anaemia.

Pethidine when given with duloxetine (SSRIs) may increase serotonergic effects.

Sedative medicines such as benzodiazepines or related drugs:

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

There is inadequate evidence of safety in human pregnancy, but the drug has been in widely use for many years without apparent ill consequence. Animal studies have not shown any hazard.

As with all drugs during pregnancy care should be taken in assessing the risk to benefit ratio.

Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.

If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breast-feeding

Administration to nursing women is not recommended as pethidine may be secreted in breast milk and may cause respiratory depression in the infant.

This should be borne in mind when considering its use in patients during pregnancy or breast feeding.

Fertility

No data available

4.7. Effects on ability to drive and use machines

Pethidine may impair the mental and/or physical abilities required for driving or for operating machinery. Patients should be advised accordingly and warned not to drive or to operate machines while taking pethidine as it may cause drowsiness and reduce alertness.

The ability to drive or use machines may be severely affected during and for some time after administration of pethidine. This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive

• Do not drive until you know how the medicine affects you

• It is an offence to drive while under the influence of this medicine

• However, you would not be committing an offence (called 'statutory defence') if:

o The medicine has been prescribed to treat a medical or dental problem and

o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and It was not affecting your ability to drive safely

4.8. Undesirable effects

The information below lists reported adverse reactions, ranked using the following frequency classification:

Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

System Organ Class

Frequency

Adverse Event

Immune system disorders

Not known

General hypersensitivity reactions

Psychiatric disorders

Not known

Drug dependence (see section 4.4), confusion, mood altered, mild euphoria, hallucinations, dysphoria, agitation, anxiety, nervousness. Increased risk of delirium in elderly patients.

Nervous system disorders

Not known

Drowsiness, dizziness, tremor, convulsions, headache, CNS excitation, syncope, light-headedness, sedation

Eye disorders

Not known

Visual disturbances, dry eye, miosis

Ear and labyrinth disorders

Not known

Vertigo

Cardiac disorders

Not known

Tachycardia, bradycardia, palpitations

Vascular disorders

Not known

Flushing of face, orthostatic hypotension, hypotension1, hypertension, vasodilatation

Respiratory, thoracic and mediastinal disorders

Not known

Respiratory depression1

Gastrointestinal disorders

Not known

Nausea, vomiting, dry mouth, constipation

Hepatobiliary disorders

Not known

Biliary or Ureteric spasm

Skin and subcutaneous tissue disorders

Not known

Sweating, rash, urticaria, pruritis

Musculoskeletal and connective tissue disorders

Not known

Uncoordinated muscle movements, muscle twitching

Renal and urinary disorders

Not known

Difficulty in micturition, renal colic, urinary retention

Reproductive system and breast disorders

Not known

Sexual dysfunction

General disorders and administration site conditions

Uncommon

Not known

Drug withdrawal syndrome

Hypothermia, weakness, injection site reactions including pain, induration and irritation, wheal and flare over the vein with intravenous injection

Investigations

Not known

Corneal reflex decreased

1The most serious adverse effects of pethidine are respiratory depression and hypotension. Rapid intravenous administration of pethidine increases the incidence of these effects and may result in serious respiratory depression and hypotension with tachycardia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms

Signs of acute overdosage may include respiratory depression, CNS depression with extreme somnolence progressing to incoordination, stupor or coma, convulsions, CNS stimulation, cyanosis, miosis, skeletal muscle flaccidity or tremors, cold, clammy skin, hypothermia, bradycardia, hypotension and shock.

In severe overdosage, apnoea, circulatory collapse, pulmonary oedema, mydriasis, cardiac arrest and death may occur.

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Management

Treatment is supportive. Primary attention should be directed at correcting respiratory failure and shock. A patent airway should be established and assisted or controlled ventilation should be provided. If signs of CNS toxicity are exhibited the use of pethidine should be discontinued. Narcotic antagonists may be required if there is evidence of significant respiratory or cardiovascular depression.

Naloxone is a specific antidote used to counteract respiratory depression and coma resulting from opioid overdosage. Naloxone should be given intravenously as soon as possible and repeated every 2-3 minutes if necessary.

Intravenous fluids, oxygen, vasopressors and other supportive measures may be required in the management of shock. An anticonvulsant may be required if seizures occur.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • MIALGIN 100 mg/2 ml prescriptionPETHIDINUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

💬 Ask about this leaflet

Ask anything about Pethidine Injection BP 50mg/ml. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →